European Society of Hypertension position paper on renal denervation 2021
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
This ESH Position Paper 2021 with updated proposed recommendations was deemed necessary after the publication of a set of new pivotal sham-controlled randomized clinical trials (RCTs), which provided important information about the efficacy and safety of endovascular device-based renal denervation (RDN) for hypertension treatment. RDN is effective in reducing or interrupting the sympathetic signals to the kidneys and decreasing whole body sympathetic activity. Five independent, fully completed, sham-controlled RCTs provide conclusive evidence that RDN lowers ambulatory and office blood pressure (BP) to a significantly greater extent than sham treatment. BP-lowering efficacy is evident both in patients with and without concomitant antihypertensive medication. The average decrease of 10 mmHg in office BP is estimated to lower the incidence of cardiovascular events by 25–30%, based on meta-analyses of RCTs using pharmacological treatment. Neither peri-procedural, nor short-term or long-term adverse events or safety signals (available up to 3 years) have been observed. Implementing RDN as an innovative third option in the armamentarium of antihypertensive treatment requires a structured process that ensures the appropriate performance of the endovascular RDN procedure and adequate selection of hypertensive patients. The latter should also incorporate patients’ perspective and preference that needs to be respected in a shared decision-making process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01225-8 · Cited by 3,755
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001940 · Cited by 2,885
Self-citationA Controlled Trial of Renal Denervation for Resistant Hypertension
Bhatt, D. L., Kandzari, D. E., O'Neill, W. W., D'Agostino, R., Flack, J. M., Katzen, B. T., Leon, M. B., Liu, M., Mauri, L., Negoita, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402670 · Cited by 2,186
Rahimi, K., Bidel, Z., Nazarzadeh, M., Copland, E., Canoy, D., Ramakrishnan, R., Pinho-Gomes, A.-C., Woodward, M., Adler, A., Agodoa, L., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00590-0 · Cited by 1,074
Self-citationAzizi, M., Schmieder, R. E., Mahfoud, F., Weber, M. A., Daemen, J., Davies, J., Basile, J., Kirtane, A. J., Wang, Y., Lobo, M. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31082-1 · Cited by 740
Self-citationBöhm, M., Kario, K., Kandzari, D. E., Mahfoud, F., Weber, M. A., Schmieder, R. E., Tsioufis, K., Pocock, S., Konstantinidis, D., Choi, J. W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30554-7 · Cited by 606
Self-citationAzizi, M., Sanghvi, K., Saxena, M., Gosse, P., Reilly, J. P., Levy, T., Rump, L. C., Persu, A., Basile, J., Bloch, M. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00788-1 · Cited by 439
Self-citationThomopoulos, C., Parati, G., & Zanchetti, A. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000378 · Cited by 388
Kario, K., Hoshide, S., Mizuno, H., Kabutoya, T., Nishizawa, M., Yoshida, T., Abe, H., Katsuya, T., Fujita, Y., Okazaki, O., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.049730 · Cited by 324
Self-citationFunction of Renal Nerves in Kidney Physiology and Pathophysiology
Osborn, J. W., Tyshynsky, R., & Vulchanova, L. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-091656 · Cited by 171 · cited 3×
“These in turn stimulate increased central sympathetic outflow, with the consequence of increased peripheral vascular resistance (vasoconstriction of the resistance vessels), thereby aggravation of BP-induced left ventricular hypertrophy, and a progression of cardiovascular and renal damage [3,4].”
BackgroundInfluential
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Self-citation(2022) · PubMed Central · doi:10.6515/acs.202205_38(3).20220321a · Cited by 117
Ogoyama, Y., Tada, K., Abe, M., Nanto, S., Shibata, H., Mukoyama, M., Kai, H., Arima, H., & Kario, K. (2022) · Hypertension Research · doi:10.1038/s41440-021-00761-8 · Cited by 59
Self-citationRenal denervation in patients with chronic kidney disease: current evidence and future perspectives
Schmieder, R. E. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac189 · Cited by 39
“Renal denervation is becoming a relevant treatment option for hypertension, as confirmed by the latest position statements and consensus documents from international [5, 6, 64] and national societies.”
BackgroundSelf-citation
Metadata
- Authors
- Schmieder, R. E., Mahfoud, F., Mancia, G., Azizi, M., Böhm, M., Dimitriadis, K., Kario, K., Kroon, A. A., D Lobo, M., Ott, C., Pathak, A., Persu, A., Scalise, F., Schlaich, M., Kreutz, R., & Tsioufis, C.
- Venue
- Journal of Hypertension
- Published
- 2021-07-13
- Volume
- 39
- Issue
- 9
- Pages
- 1733-1741
- ISSN
- 0263-6352 (ISSN-L)
- 1473-5598
- OpenAlex
- W3178407368
- Cited by
- 131
- References
- 11
- FWCI
- 17.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: European Society of Hypertension position paper on renal denervation 2021. https://app.cochat.ai/papers/10.1097/hjh.0000000000002933
- The paper
- Schmieder, R. E., Mahfoud, F., Mancia, G., Azizi, M., Böhm, M., Dimitriadis, K., Kario, K., Kroon, A. A., D Lobo, M., Ott, C., Pathak, A., Persu, A., Scalise, F., Schlaich, M., Kreutz, R., & Tsioufis, C. (2021). European Society of Hypertension position paper on renal denervation 2021. Journal of Hypertension. https://doi.org/10.1097/hjh.0000000000002933
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.